Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2

NCT05487651 is registered in ClinicalTrials.gov with Athenex, Inc. as lead sponsor.

NCT NCT05487651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05487651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2
Lead sponsor
Athenex, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2022
Completion date
December 31, 2024
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

all, adult b cell, all, childhood, b-cell leukemia, b-cell lymphoma, cll/sll, dlbcl - diffuse large b cell lymphoma, nhl, relapsed, adult